A groundbreaking preclinical study reveals how targeting a viral enzyme with a new drug could prevent long-COVID complications, offering hope for millions and a powerful tool for future coronavirus threats.
Study: A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID
Over 77 million people globally have experienced lingering symptoms after recovering from coronavirus disease 2019 (COVID-19), yet an effective and reliable prophylactic measure for long coronavirus disease (long COVID) remains elusive.
In a recent preclinical study published in the journal Nature Communications, a team of researchers in Australia investigated a new antiviral compound that may prevent these long-term effects of long COVID-19. This novel antiviral…